Anti-α actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1. - Université de Bretagne Occidentale Accéder directement au contenu
Article Dans Une Revue Alimentary Pharmacology and Therapeutics Année : 2012

Anti-α actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1.

Résumé

BACKGROUND: We reported that combined presence of autoantibodies (Abs) against filamentous-actin (AFA) and α-actinin are specific for autoimmune hepatitis type 1 (AIH-1) diagnosis. AIM: To explore our data and assess whether anti-α-actinin and AFA Abs could be used as indicators of response to treatment and predictors of AIH-1 flares in a large cohort of AIH-1 patients. METHODS: Seven hundred and sixty-four serial serum samples of 86 consecutive AIH-1 patients, 509 pathological and 110 normal controls were tested for the presence of anti-α-actinin and AFA Abs by an in-house IgG-specific ELISA and a standardised commercially available ELISA respectively. Patients sera were divided into baseline group (active disease before treatment initiation, n = 86) and then according to treatment response into group A-responders (n = 40 patients), group B-relapsers/incomplete responders (n = 37 patients) and group C-not-treated (n = 9 patients). RESULTS: Anti-α-actinin and AFA levels were significantly higher at baseline. Double reactivity against α-actinin and AFA was associated with disease activity (OR 4.9; 95% CI: 2.7-9). Anti-α-actinin optical densities (ODs) before treatment decreased significantly at first remission (P < 0.05). Treatment response was associated with anti-α-actinin Abs negativity before treatment (OR 3.4; 95% CI: 1.3-8.9) and absence of double positivity for anti-α-actinin and AFA Abs before treatment (OR 3.8; 95% CI: 1.4-10.4). Responders had lower baseline levels of anti-α-actinin than relapsers and/or incomplete responders (P = 0.002). Binary logistic regression revealed lower levels of anti-α-actinin as the only independent predictors of response (P = 0.05). CONCLUSIONS: Anti-α-actinin Abs at baseline appear to predict treatment response and therefore they might be used for monitoring treatment outcome in AIH-1.

Domaines

Immunologie

Dates et versions

hal-00771192 , version 1 (08-01-2013)

Identifiants

Citer

K. Zachou, K. Oikonomou, Yves Renaudineau, A. Chauveau, N. Gatselis, et al.. Anti-α actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1.. Alimentary Pharmacology and Therapeutics, 2012, 35 (1), pp.116-25. ⟨10.1111/j.1365-2036.2011.04908.x⟩. ⟨hal-00771192⟩
62 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More